Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: Results of a double-blind, placebo-controlled 26-week study

International Clinical Psychopharmacology

Volumn 26, Issue 5, 2011, Pages 243-251

  Greist, John H ^a   Liu Dumaw, Maria ^b   Schweizer, Edward ^c   Feltner, Douglas ^d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b MLD Consulting   (United States)

^c Paladin Consulting Group   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

anxiety disorders; phobic disorders; pregabalin; relapse; social anxiety disorder

Indexed keywords

PLACEBO; PREGABALIN;

ABNORMAL THINKING; ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INFECTION; INSOMNIA; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SOCIAL PHOBIA; SOMNOLENCE;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PHOBIC DISORDERS; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051785794     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3283491fd5     Document Type: Article

References (35)

1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al.; ESEMeD/MHEDEA 2000 Investigators, European Study of the Epidemiology of Mental Disorders (ESEMeD) Project (2004). Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 420:38-46.
2. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ; WFSPB Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry 9:248-312.
3. Beard C, Moitra E, Weisberg RB, Keller MB (2010). Characteristics and predictors of social phobia course in a longitudinal study of primary-care patients. Depress Anxiety 27:839-845.
4. 2-delta type 1 genetically modified mice. Brain Res 1075:68-80.
5. Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, et al. (2005). Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 162:1179-1187. (Pubitemid 40770702)
6. Connor KM, Davidson JR, Potts NL, Tupler LA, Miner CM, Malik ML, et al. (1998). Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol 18:373-378. (Pubitemid 28462626)
7. Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig GM, et al. (2008). Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 136:419-431.
8. Elashoff JD (1999). NQuery advisor version 3.0 users guide. Statistical Solutions, Los Angeles, CA.
9. Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC (2008). Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 23:18-28. (Pubitemid 350294866)
10. Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R (2011). Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebocontrolled, fixed-dose study. Int Clin Psychopharmacol [Epub ahead of print].
11. Guy W (1976). ECDEU assessment manual for psychopharmacology. Rockville, MD: Department of Health, Education and Welfare.
12. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
13. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
14. Heimberg RG (2002). Cognitive-behavioral therapy for social phobia: current status and future directions. Biol Psychiatry 51:101-108. (Pubitemid 34093798)
15. Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR, et al. (1999). Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med 29:199-212. (Pubitemid 29034537)
16. Ipser JC, Kariuki CM, Stein DJ (2008). Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother 8:235-257. (Pubitemid 351281112)
17. Kessler RC, Wang PS (2008). The descriptive epidemiology of commonly occurring mental disorders in the United States. Annu Rev Public Health 29:115-129. (Pubitemid 351600402)
18. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627. (Pubitemid 40973437)
19. Leon AC, Shear MK, Portera L, Klerman GL (1992). Assessing impairment in patients with panic disorders: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 27:78-82.
20. Marks I, Mathews A (1979). Brief standard self-rating for phobic patients. Behav Res Ther 17:263-267. (Pubitemid 10232022)
21. Marubini E, Valsecchi MG (1995). Analysing survival data from clinical trials and observational studies. New York, New York: John Wiley and Sons. pp. 127-141.
22. Montgomery SA (2006). Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother 7:2139-2154.
23. Montgomery SA, Nil R, Dürr-Pal N, Loft H, Boulenger JP (2005). A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 66:1270-1278. (Pubitemid 41546506)
24. Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, et al. (2004). Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 24:141-149. (Pubitemid 38380837)
25. Rickels K, Case WG, Schweizer E, Garcia-Espana F, Fridman R (1990). Benzodiazepine dependence: management of discontinuation. Psychopharmacol Bull 26:63-68. (Pubitemid 20322247)
26. Rodebaugh TL, Holaway RM, Heimberg RG (2004). The treatment of social anxiety disorder. Clin Psychol Rev 24:883-908. (Pubitemid 39388876)
27. Ruscio AM, Brown TA, Chiu WT, Sareen J, Stein MB, Kessler RC (2008). Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication. Psychol Med 38:15-28. (Pubitemid 350275216)
28. Saarni SI, Suvisaari J, Sintonen H, Pirkola S, Koskinen S, Aromaa A, et al. (2007). Impact of psychiatric disorders on health-related quality of life: general population survey. Br J Psychiatry 190:326-332. (Pubitemid 46580682)
29. SAS Institute (1989). SAS/Stat user's guide volumes 1 and 2, version 612. Cary, NC: SAS Institute.
30. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The Mini-International Neuropsychiatric Interview (M. I. N. I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20);22-33; quiz 34-57. (Pubitemid 29001829)
31. Stein MB, Kean YM (2000). Disability and quality of life in social phobia: epidemiologic findings. Amer J Psychiatry 157:1606-1613.
32. Stein DJ, Versiani M, Hair T, Kumar R (2002). Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 59:1111-1118. (Pubitemid 35424021)
33. Stein DJ, Westenberg HG, Yang H, Li D, Barbato LM (2003). Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12-to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 6:317-323. (Pubitemid 38146249)
34. 2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 73:137-150. (Pubitemid 46329329)
35. Walker JR, Van Ameringen MA, Swinson R, Bowen RC, Chokka PR, Goldner E, et al. (2000). Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 20:636-644.